- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06378801
Radicle Relaxation 24: A Study of Health and Wellness Products on Stress and Related Health Outcomes
Radicle Relaxation™ 24: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Stress and Related Health Outcomes
Study Overview
Status
Conditions
Detailed Description
This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States.
Eligible participants will (1) endorse a desire for less stress (2) have the opportunity for meaningful improvement (at least 20%) in their primary health outcome, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.
Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded.
Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Del Mar, California, United States, 92014
- Radicle Science, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults, at least 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities. Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
- Resides in the United States
- Endorses less stress as a primary desire
- Has the opportunity for at least 20% improvement in their primary health outcome
- Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion Criteria:
- Reports being pregnant, trying to become pregnant, or breastfeeding
- Unable to provide a valid US shipping address and mobile phone number
- Reports current enrollment in another clinical trial
- Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
- Unable to read and understand English
- Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
- Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients. NYHA (New York Heart Association) Class Ill or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
- Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients. Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOls (monoamine oxidase inhibitors), or thyroid products
- Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s)
- Lack of reliable daily access to the internet
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Control 1
Relaxation Product Form 1 - control
|
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
|
Experimental: Active Product 1.1
Relaxation Product Form 1 - active product 1
|
Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.
|
Placebo Comparator: Placebo Control 2
Relaxation Product Form 2 - control
|
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
|
Experimental: Active Product 2.1
Relaxation Product Form 2 - active product 1
|
Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in stress
Time Frame: 6 weeks
|
Mean difference in stress score as assessed by National Institutes of Health (NIH) Toolbox Perceived Stress Survey (scale 10-50; where lower scores correspond to less stress)
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mood (emotional distress-depression)
Time Frame: 6 weeks
|
Mean difference in emotional distress score as assessed by PROMIS Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)
|
6 weeks
|
Change in cognitive function
Time Frame: 6 weeks
|
Mean difference in cognitive function score as assessed by PROMIS Cognitive Function 4A (scale 4-20; where lower scores correspond to worse cognitive function)
|
6 weeks
|
Change in feelings of anxiety
Time Frame: 6 weeks
|
Mean difference in anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)
|
6 weeks
|
Minimal clinically important difference (MCID) in stress
Time Frame: 6 weeks
|
Likelihood of experiencing minimal clinically important difference in stress score as assessed by National Institutes of Health (NIH) Toolbox Perceived Stress Survey (scale 10-50; where lower scores correspond to less stress)
|
6 weeks
|
Minimal clinically important difference (MCID) in feelings of anxiety
Time Frame: 6 weeks
|
Likelihood of experiencing minimal clinically important difference in anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 4A (scale 4-20; with higher scores corresponding to more severe anxiety)
|
6 weeks
|
Minimal clinically important difference (MCID) in cognitive function
Time Frame: 6 weeks
|
Likelihood of experiencing minimal clinically important difference in cognitive function score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function 4A (scale 4-20; where lower scores correspond to worse cognitive function)
|
6 weeks
|
Minimal clinically important difference (MCID) in mood (emotional distress-depression)
Time Frame: 6 weeks
|
Likelihood of experiencing minimal clinically important difference in emotional distress score as assessed by Patient Reported Outcome Measurement System (PROMIS) Emotional Distress- Depression 4A (scale 4-20; with higher scores corresponding to greater levels of emotional distress)
|
6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in concentration of at-home (direct-to-consumer) specimen assays either saliva, blood or stool
Time Frame: 6 weeks
|
Mean difference in specimen assays as surrogates and/or markers for health outcomes.
(Optional; among consented participants only) Potentially include saliva (IgG, cytokines, DHEA-S, Estradiol, Progesterone, Testosterone, Cortisol, Melatonin, CRP) blood all in one panel 1 outcome (1 drop) (Cortisol, Homocysteine, Ferritin, TSH, HbA1c, Insulin, Vitamin D, DHEA-S, Testosterone, Estradiol, FSH, Total Cholesterol, HDL, LDL, Triglycerides, ApoA1, ApoB).
Stool (microbial diversity).
Values will vary based on optional biomarker selected
|
6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emily K. Pauli, PharmD, Radicle Science, Inc
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- RADX-P-2408
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
University of PadovaRecruitingStress | Stress Disorder | Work Related StressItaly
-
Dana-Farber Cancer InstituteEnrolling by invitationStress | Post Traumatic Stress Disorder | Work Related StressUnited States
-
Syracuse VA Medical CenterUS Department of Veterans AffairsCompletedEmotional Stress | Psychological Stress | Life StressUnited States
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
University of Sao PauloCompleted
-
Royal Cornwall Hospitals TrustEnrolling by invitationStress | Stress, Psychological | Stress, JobUnited Kingdom
-
Taichung Veterans General HospitalUnknown
-
Northumbria UniversityVolac International LtdRecruitingStress | Mood | Physiological StressUnited Kingdom
Clinical Trials on Placebo Control Form 1
-
Radicle ScienceRecruitingStress | AnxietyUnited States
-
Radicle ScienceRecruitingCognitive FunctionUnited States
-
Radicle ScienceRecruitingSleep Disorder | Sleep | Sleep DisturbanceUnited States
-
Radicle ScienceCompletedStress | AnxietyUnited States
-
Radicle ScienceActive, not recruitingFatigue | EnergyUnited States
-
Radicle ScienceCompletedCognitive FunctionUnited States
-
Radicle ScienceRecruitingAbdominal Pain | Digestion | GI DisordersUnited States
-
Radicle ScienceActive, not recruitingPain | Neuropathic Pain | Nociceptive PainUnited States
-
Radicle ScienceCompletedSleep Disorder | Sleep | Sleep DisturbanceUnited States
-
Radicle ScienceCompletedAbdominal Pain | Digestion | GI DisordersUnited States